NEUP
Income statement / Annual
Last year (2025), Neuphoria Therapeutics Inc.'s total revenue was $15.65 M,
and the percentage change from the previous year is not available.
In 2025, Neuphoria Therapeutics Inc.'s net income was -$369.63 K.
See Neuphoria Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$15.65 M |
$0.00 |
$0.00 |
$383.16 K |
$927.54 K |
$32.06 K |
$7.40 M |
$11.94 M |
$27.15 M |
$5.21 M |
| Cost of Revenue |
$662.89 K
|
$662.99 K
|
$671.48 K
|
$16.00 M
|
$1.69 M
|
$0.00
|
$12.13 M
|
$25.38 M
|
$24.22 M
|
$24.77 M
|
| Gross Profit |
$14.99 M
|
-$662.99 K
|
-$671.48 K
|
-$9.98 M
|
-$1.27 M
|
$32.06 K
|
$2.68 M
|
-$13.43 M
|
$2.84 M
|
$5.21 M
|
| Gross Profit Ratio |
0.96
|
0
|
0
|
-26.04
|
-1.37
|
1
|
0.36
|
-1.12
|
0.1
|
1
|
| Research and Development Expenses |
$9.01 M
|
$14.10 M
|
$19.67 M
|
$23.25 M
|
$4.33 M
|
$4.00 M
|
$6.29 M
|
$18.55 M
|
$18.61 M
|
$18.50 M
|
| General & Administrative Expenses |
$7.77 M
|
$8.47 M
|
$13.41 M
|
$7.42 M
|
$4.24 M
|
$3.33 M
|
$6.55 M
|
$4.97 M
|
$5.72 M
|
$7.89 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$262.44 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.77 M
|
$8.47 M
|
$13.41 M
|
$7.69 M
|
$4.24 M
|
$3.33 M
|
$6.55 M
|
$4.97 M
|
$5.72 M
|
$7.89 M
|
| Other Expenses |
-$662.89 K
|
-$4.68 M
|
$0.00
|
-$7.20 M
|
$2.68 M
|
-$1.11 M
|
$7.26 M
|
$523.58 K
|
$8.32 M
|
$510.24 K
|
| Operating Expenses |
$16.12 M
|
$17.89 M
|
$33.09 M
|
$23.74 M
|
$11.25 M
|
$6.23 M
|
$20.09 M
|
$24.04 M
|
$32.66 M
|
$26.89 M
|
| Cost And Expenses |
$16.78 M
|
$17.89 M
|
$33.09 M
|
$39.80 M
|
$12.94 M
|
$6.23 M
|
$32.27 M
|
$61.49 M
|
$56.97 M
|
$26.89 M
|
| Interest Income |
$166.50 K
|
$220.10 K
|
$486.39 K
|
$9.87 K
|
$4.29 K
|
$39.13 K
|
$197.95 K
|
$422.32 K
|
$925.02 K
|
$915.95 K
|
| Interest Expense |
$0.00
|
$0.00
|
$29.59 K
|
$26.87 K
|
$1.08 M
|
$1.24 M
|
$1.66 M
|
$1.51 M
|
$1.51 M
|
$1.41 M
|
| Depreciation & Amortization |
$1.01 M
|
$992.56 K
|
$998.17 K
|
$1.61 M
|
$1.28 M
|
$1.68 M
|
$1.43 M
|
$1.67 M
|
$1.74 M
|
$1.94 M
|
| EBITDA |
-$121.90 K |
-$25.65 M |
-$31.45 M |
-$30.25 M |
-$4.51 M |
-$1.23 M |
-$11.21 M |
-$22.38 M |
-$3.75 M |
-$14.16 M |
| EBITDA Ratio |
-0.01
|
0
|
0
|
-78.95
|
-4.87
|
-38.34
|
-1.52
|
-1.87
|
-0.14
|
-2.72
|
| Operating Income Ratio |
-0.07
|
0
|
0
|
-80.95
|
-9.66
|
-193.19
|
-1.45
|
-1.78
|
-0.51
|
-4.16
|
| Total Other Income/Expenses Net |
$291.09 K
|
$2.31 M
|
$695.55 K
|
-$886.03 K
|
$2.28 M
|
$2.05 M
|
$3.82 M
|
$2.00 M
|
$6.02 M
|
$8.74 M
|
| Income Before Tax |
-$838.00 K
|
-$15.58 M
|
-$32.39 M
|
-$31.90 M
|
-$6.68 M
|
-$4.14 M
|
-$6.94 M
|
-$19.28 M
|
-$4.79 M
|
-$12.94 M
|
| Income Before Tax Ratio |
-0.05
|
0
|
0
|
-83.26
|
-7.2
|
-129.16
|
-0.94
|
-1.61
|
-0.18
|
-2.48
|
| Income Tax Expense |
-$468.37 K
|
$87.32 K
|
-$209.47 K
|
-$278.77 K
|
-$140.82 K
|
-$142.65 K
|
-$165.80 K
|
-$852.96 K
|
$401.57 K
|
-$534.22 K
|
| Net Income |
-$369.63 K
|
-$15.49 M
|
-$32.18 M
|
-$22.94 M
|
-$6.53 M
|
-$4.89 M
|
-$6.77 M
|
-$18.43 M
|
-$5.19 M
|
-$12.40 M
|
| Net Income Ratio |
-0.02
|
0
|
0
|
-59.87
|
-7.04
|
-152.55
|
-0.92
|
-1.54
|
-0.19
|
-2.38
|
| EPS |
-0.23 |
-0.1 |
-0.24 |
-0.2 |
-0.1 |
-0.11 |
-0.16 |
-0.46 |
-0.13 |
-0.33 |
| EPS Diluted |
-0.23 |
-0.1 |
-0.24 |
-0.2 |
-0.1 |
-0.11 |
-0.16 |
-0.46 |
-0.13 |
-0.33 |
| Weighted Average Shares Out |
$1.62 M
|
$149.80 M
|
$122.39 M
|
$112.78 M
|
$65.00 M
|
$45.41 M
|
$43.44 M
|
$40.19 M
|
$40.11 M
|
$38.10 M
|
| Weighted Average Shares Out Diluted |
$1.62 M
|
$149.80 M
|
$122.39 M
|
$112.78 M
|
$65.00 M
|
$45.41 M
|
$43.44 M
|
$40.19 M
|
$40.11 M
|
$38.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
